Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1816 to 1830 of 7682 results

  1. Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent TS ID 11808

    Awaiting development [GID-TA11200] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Ovarian, fallopian tube, peritoneal cancer (platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128]

    Awaiting development [GID-TA11216] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]

    Awaiting development [GID-TA11219] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor TS ID 11822

    Awaiting development [GID-TA11229] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Semaglutide for treating type 2 diabetes and associated peripheral arterial disease TS ID 11791

      Status ...

    Technology appraisal guidance
    Topic selection

  6. Social work interventions for adults with complex needs (including learning disabilities) and mental health needs

    Awaiting development [GID-QS10148] Expected publication date: TBC

    Quality standard
    Awaiting development

  7. Readmission to ICU within 48hrs

    Awaiting development [GID-QS10105] Expected publication date: TBC

    Quality standard
    Awaiting development

  8. TVB-009 (denosumab biosimilar) for treating postmenopausal osteoporosis in people aged 60 to 90 TS ID 11807

      Status ...

    Technology appraisal guidance
    Topic selection

  9. Subcutaneous belimumab for treating systemic lupus erythematosus in children aged 5 to 17 TS ID 11828

      Status ...

    Technology appraisal guidance
    Topic selection

  10. Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over TS ID 11838

    Awaiting development [GID-TA11275] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 TS ID 11839

    Awaiting development [GID-TA11276] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Invimestrocel for treating acute ischaemic stroke within 18 to 36 hours of onset TS ID 10190

    Awaiting development [GID-TA11283] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Ceftobiprole medocaril for treating community- or hospital-acquired pneumonia in people 3 months to 17 years TS ID 11819

      Status ...

    Technology appraisal guidance
    Topic selection

  14. Baricitinib for treating moderate to severe atopic dermatitis in children and young people aged 2 to 17 [TS ID 10639]

      Status ...

    Technology appraisal guidance
    Topic selection

  15. NPJ5008 for treating malignant hyperthermia TS ID 11829

      Status ...

    Technology appraisal guidance
    Topic selection